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1. INTRODUCTION {#apt14421-sec-0006}
===============

Crohn\'s disease is a chronic, relapsing‐remitting inflammation of the intestinal tract. Inhibition of tumour necrosis factor‐α (TNF) was shown to induce remission in patients with Crohn\'s disease.[1](#apt14421-bib-0001){ref-type="ref"}, [2](#apt14421-bib-0002){ref-type="ref"}, [3](#apt14421-bib-0003){ref-type="ref"}, [4](#apt14421-bib-0004){ref-type="ref"} Certolizumab pegol is a recombinant, humanised, Fc‐free, polyethylene glycol‐conjugated antigen‐binding fragment specific for human TNF, and is effective at reducing signs and symptoms of moderately to severely active Crohn\'s disease and maintaining clinical response in adult patients who have had an inadequate response to conventional therapy.[2](#apt14421-bib-0002){ref-type="ref"}, [4](#apt14421-bib-0004){ref-type="ref"}, [5](#apt14421-bib-0005){ref-type="ref"}, [6](#apt14421-bib-0006){ref-type="ref"}

Not all patients with Crohn\'s disease respond to treatment with TNF antagonists and both the time and the magnitude of response to therapy is variable.[4](#apt14421-bib-0004){ref-type="ref"}, [7](#apt14421-bib-0007){ref-type="ref"}, [8](#apt14421-bib-0008){ref-type="ref"} Some variation has been associated with the development of antidrug antibodies (ADAb), which have been associated with increased clearance of drug,[9](#apt14421-bib-0009){ref-type="ref"} but other disease‐ and patient‐related factors also influence drug concentrations.[7](#apt14421-bib-0007){ref-type="ref"} Factors that influence certolizumab pegol concentrations were examined in a population pharmacokinetic model for certolizumab pegol in patients with Crohn\'s disease.[10](#apt14421-bib-0010){ref-type="ref"} The model, which used data from 2157 patients with Crohn\'s disease treated with certolizumab pegol in nine clinical trials, followed a conventional population pharmacokinetic model‐building approach. Only baseline covariates were used, and thus individually predicted clearance remained constant over time. A refined population pharmacokinetic model was developed subsequently,[11](#apt14421-bib-0011){ref-type="ref"} that takes into account the time‐varying nature of patient characteristics and reduces the inter‐patient variability of certolizumab pegol clearance estimates to \< 20%, which is considered low for a biologic. The revised model also includes certolizumab pegol ADAb concentration as a continuous variable, allowing for evaluation of the concentration‐dependent effect of ADAb on certolizumab pegol clearance. Other covariates that explained inter‐patient variability in apparent drug clearance were C‐reactive protein, albumin, as well as other, less disease‐related covariates such as body weight and gender. By taking into account the time‐varying nature of these covariates, the refined population pharmacokinetic model constitutes an important improvement over the previous model, which is more reflective of patient drug exposure with sustained treatment, as patient and disease characteristics of patients with Crohn\'s disease are expected to change over time depending on their response to therapy.

Using the refined population pharmacokinetic model to precisely simulate drug concentrations at exact time points in individual patients, we were able to conduct a pooled analysis of nine clinical trials of certolizumab pegol in Crohn\'s disease, each with a seemingly different trial design, encompassing various dosing regimens and sampling time‐points. To our knowledge, this constitutes the largest combined exposure‐response analysis of any TNF antagonist on the market to date. This analysis aimed to evaluate the association between various measures of certolizumab pegol exposure and clinical and biomarker outcome measures. In addition, we evaluated the effects of covariates that may influence the exposure‐response relationship of certolizumab pegol during induction (assessed at week 6) and maintenance (assessed at week 26) therapy with certolizumab pegol, as well as the certolizumab pegol concentrations that are associated with achieving these outcomes.

2. METHODS {#apt14421-sec-0007}
==========

2.1. Data sources {#apt14421-sec-0008}
-----------------

This analysis was conducted using pooled data from nine clinical trials of certolizumab pegol in patients with Crohn\'s disease,[10](#apt14421-bib-0010){ref-type="ref"} including C87005,[12](#apt14421-bib-0012){ref-type="ref"} C87031 (NCT00152490),[2](#apt14421-bib-0002){ref-type="ref"} C87032 (NCT00152425),[4](#apt14421-bib-0004){ref-type="ref"} C87037 (NCT00291668),[6](#apt14421-bib-0006){ref-type="ref"} C87042 (NCT00308581),[13](#apt14421-bib-0013){ref-type="ref"} C87043 (NCT00297648),[1](#apt14421-bib-0001){ref-type="ref"} C87047 (NCT00329550),[6](#apt14421-bib-0006){ref-type="ref"} C87048 (NCT00329420)[6](#apt14421-bib-0006){ref-type="ref"} and C87085 (NCT00552058)[14](#apt14421-bib-0014){ref-type="ref"} (Figure [S1](#apt14421-sup-0001){ref-type="supplementary-material"}). All study protocols and consent forms were approved by institutional review boards or ethics committees at the study sites, and studies were conducted in accordance with the principles of good clinical practice and the Declaration of Helsinki. All patients provided written informed consent before study participation.

Certolizumab pegol concentrations were measured with a sandwich enzyme‐linked immunosorbent assay (ELISA), which was validated in line with the regulatory requirements of the Food and Drug Administration and the European Medicines Agency for bioanalytical methods, as previously described, with 0.41 μg/mL as the lower limit of quantification.[10](#apt14421-bib-0010){ref-type="ref"} The ELISA was developed to exclusively support pharmacokinetic analyses across a range of indications (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and Crohn\'s disease) for UCB Pharma. ADAb to certolizumab pegol were measured with a drug‐sensitive double antigen ( = bridging) ELISA, as previously described, and samples were classified as ADAb positive if the concentration of antibodies was \>2.4 units/mL.[10](#apt14421-bib-0010){ref-type="ref"}

Certolizumab pegol concentration‐time data in Crohn\'s disease were adequately described by a population pharmacokinetic model with first‐order absorption and one‐compartment disposition with linear, time‐dependent elimination that included ADAb to certolizumab pegol as a continuous variable in the structural model and took into account the time‐varying nature of covariates, as described elsewhere.[11](#apt14421-bib-0011){ref-type="ref"} This model was used to simulate various certolizumab pegol exposure measures including intermediate and trough concentrations at exact time points as well as area under the concentration‐time curve, for each patient available for this analysis, given the dosing history of that patient and individual time‐varying covariate values.

2.2. Efficacy outcomes {#apt14421-sec-0009}
----------------------

Efficacy outcomes at weeks 6 and 26 included clinical response (defined as a Crohn\'s disease activity index decrease from baseline of ≥ 100 points), clinical remission (defined as a Crohn\'s disease activity index score of ≤ 150), biological remission (defined by C‐reactive protein ≤ 5 mg/L or faecal calprotectin ≤ 250 μg/g) and a composite endpoint (Crohn\'s disease activity index ≤ 150 and faecal calprotectin ≤ 250 μg/g).

2.3. Analyses {#apt14421-sec-0010}
-------------

Descriptive statistics were used to summarise patient and pharmacological data. Certolizumab pegol concentrations were compared between patients achieving or not achieving the efficacy outcome using a Wilcoxon two‐sample test. Certolizumab pegol concentrations were also categorised into quartiles, and the trend of patients achieving the efficacy endpoints across quartiles was evaluated using the one‐sided Cochran‐Armitage Trend test. Multivariable logistic regression was carried out to identify covariates associated with exposure‐response relationship to certolizumab pegol therapy, including continuous variables: age, gender, weight, certolizumab pegol concentration (log‐transformed), disease duration, haematocrit, albumin, C‐reactive protein and Crohn\'s disease activity index and categorical variables: ADAb to certolizumab pegol, prior anti‐TNF treatment, immunosuppressant use and prior surgery. Factors not significant at the 0.05 level were removed from the model by backwards elimination. Multivariable logistic regression analyses only comprised data from two randomised, double‐blind, placebo‐controlled trials (PRECiSE1[2](#apt14421-bib-0002){ref-type="ref"} and PRECiSE2[4](#apt14421-bib-0004){ref-type="ref"}), because these were the only trials where faecal calprotectin data were recorded. Receiver operating characteristic analyses were carried out to determine optimal certolizumab pegol concentrations associated with efficacy outcomes during induction and maintenance. To maximise the sum of the specificity and sensitivity along the receiver operating characteristic curve, the Youden index was used to determine optimal certolizumab concentration thresholds.[15](#apt14421-bib-0015){ref-type="ref"} Certolizumab pegol concentration thresholds with high specificity (\> 90%) were also evaluated.

Dropouts were considered as treatment failures for these analyses, regardless of the reason(s) for discontinuation. All authors had access to the study data, and reviewed and approved this manuscript for publication.

3. RESULTS {#apt14421-sec-0011}
==========

3.1. Baseline characteristics and outcomes to therapy {#apt14421-sec-0012}
-----------------------------------------------------

Data were collected from 2157 patients with Crohn\'s disease in nine studies. Of those, 2070 subjects received at least some form of certolizumab pegol induction therapy prior to week 6 and had a baseline value available for the efficacy outcome. The median age was 35 years, 56% were female, and 92% were white (Table [S1](#apt14421-sup-0001){ref-type="supplementary-material"}). At week 6 of treatment with certolizumab pegol, 55.3% (n* = *1144/2070) achieved clinical response and 35.2% (n* = *729/2070) achieved clinical remission. Of the patients with C‐reactive protein \> 5 mg/L at baseline, 27.1% (n* = *346/1277) achieved C‐reactive protein of ≤ 5 mg/L at week 6 and of the patients with faecal calprotectin \> 250 μg/g at baseline, 13.9% (n* = *73/525) achieved faecal calprotectin of ≤ 250 μg/g at week 6.

3.2. Quartile analysis {#apt14421-sec-0013}
----------------------

A quartile analysis of simulated certolizumab pegol concentrations at week 6 provided evidence of exposure‐response relationships with certolizumab pegol concentration and outcome measures (Figure [1](#apt14421-fig-0001){ref-type="fig"}A‐E). Substantial proportions of responders were present in all quartiles, however, certolizumab pegol therapy was effective for a smaller proportion of patients in the lowest quartiles compared with the highest (Figure [1](#apt14421-fig-0001){ref-type="fig"}A‐E). The strongest exposure‐response relationship was observed for C‐reactive protein ≤ 5 mg/L and faecal calprotectin ≤ 250 μg/g, with a \~45% increase in the proportion of patients achieving the outcome from the first to fourth quartile (Figure [1](#apt14421-fig-0001){ref-type="fig"}C and D). Furthermore, a quartile analysis for a composite endpoint comprised of Crohn\'s disease activity index ≤ 150 and faecal calprotectin ≤ 250 μg/g revealed a significant relationship between certolizumab concentration and the robust efficacy outcome (*P *\< .001; Figure [1](#apt14421-fig-0001){ref-type="fig"}E).

![Quartile analyses of endpoints at week 6. \*One‐sided Cochran‐Armitage Trend test. CDAI, Crohn\'s disease activity index](APT-47-229-g001){#apt14421-fig-0001}

3.3. Certolizumab pegol exposure by efficacy outcome {#apt14421-sec-0014}
----------------------------------------------------

Patients who achieved clinical response at week 6 had significantly higher certolizumab pegol concentrations at week 2 (20.6 vs 20.3; *P = *.050), week 4 (31.0 vs 28.0 μg/mL; *P *\< .001) and week 6 (32.6 vs 29.5 μg/mL; *P *\< .001) relative to those who did not. Similarly, patients with clinical remission at week 6 had significantly higher certolizumab pegol concentrations at week 2 (20.9 vs 20.4; *P = *.047), week 4 (31.3 vs 28.8 μg/mL; *P *\< .001) and week 6 (33.7 vs 30.0 μg/mL; *P *\< .001) relative to those who did not (Table [1](#apt14421-tbl-0001){ref-type="table-wrap"}).

###### 

Relationship between measures of certolizumab pegol exposure and various outcomes at week 6

  Week 6 endpoint                                                  Week 6 endpoint achieved   *P* value[a](#apt14421-note-0003){ref-type="fn"}                                    
  ---------------------------------------------------------------- -------------------------- -------------------------------------------------- ------ ------------------------- --------
  CDAI response (decrease of ≥ 100 from baseline or CDAI ≤ 150)                                                                                                                   
  Week 2 CZP                                                       916                        20.3 (15.8, 25.4)                                  1144   20.6 (16.8, 25.6)         .050
  Week 4 CZP                                                       865                        28.0 (18.9, 37.6)                                  1143   31.0 (23.2, 39.8)         \<.001
  Week 6 CZP                                                       743                        29.5 (19.3, 38.3)                                  1128   32.6 (24.4, 41.2)         \<.001
  AUCC~Week\ 0‐6~                                                  917                        1507.1 (1057.9, 1800.0)                            1144   1704.8 (1448.8, 1939.9)   \<.001
  CDAI remission (CDAI ≤ 150)                                                                                                                                                     
  Week 2 CZP                                                       1331                       20.4 (15.9, 25.5)                                  729    20.9 (17.2, 25.5)         .047
  Week 4 CZP                                                       1280                       28.8 (20.1, 38.9)                                  728    31.3 (24.1, 39.2)         \<.001
  Week 6 CZP                                                       1154                       30.0 (20.5, 38.8)                                  717    33.7 (25.4, 41.4)         \<.001
  AUCC~Week\ 0‐6~                                                  1332                       1584.3 (1205.1, 1846.0)                            729    1716.1 (1488.0, 1940.6)   \<.001
  C‐reactive protein ≤ 5 mg/L                                                                                                                                                     
  Week 2 CZP                                                       1086                       19.1 (15.0, 23.6)                                  973    22.3 (18.4, 26.7)         \<.001
  Week 4 CZP                                                       1035                       26.8 (19.0, 35.0)                                  972    32.9 (25.7, 41.0)         \<.001
  Week 6 CZP                                                       924                        27.2 (18.6, 34.5)                                  947    36.0 (27.6, 44.0)         \<.001
  AUCC~Week\ 0‐6~                                                  1087                       1509.4 (1139.7, 1750.2)                            973    1774.9 (1494.7, 2003.4)   \<.001
  Faecal calprotectin ≤ 250 μg/g                                                                                                                                                  
  Week 2 CZP                                                       583                        19.8 (16.8, 24.6)                                  314    22.9 (20.0, 26.8)         \<.001
  Week 4 CZP                                                       563                        28.4 (22.5, 36.9)                                  314    34.9 (29.5, 41.7)         \<.001
  Week 6 CZP                                                       514                        30.0 (23.0, 37.0)                                  314    38.6 (32.5, 44.5)         \<.001
  AUCC~Week\ 0‐6~                                                  583                        1612.5 (1398.7, 1830.3)                            314    1839.7 (1664.9, 2025.0)   \<.001
  CDAI remission (CDAI ≤ 150) and faecal calprotectin ≤ 250 μg/g                                                                                                                  
  Week 2 CZP                                                       747                        20.6 (17.5, 25.9)                                  150    22.1 (19.7, 26.4)         .003
  Week 4 CZP                                                       727                        30.3 (24.0, 39.5)                                  150    34.2 (29.6, 41.3)         \<.001
  Week 6 CZP                                                       678                        32.0 (24.4, 39.9)                                  150    38.0 (32.8, 43.5)         \<.001
  AUCC~Week\ 0‐6~                                                  747                        1668.1 (1443.7, 1880.7)                            150    1826.5 (1649.0, 2005.3)   \<.001

AUCC, area under concentration‐time curve (expressed as μgd/mL); CDAI, Crohn\'s disease activity index; CZP, certolizumab pegol.

Wilcoxon two‐sample test.

John Wiley & Sons, Ltd

The concentrations of certolizumab pegol were significantly higher in patients who achieved C‐reactive protein ≤ 5 mg/L at week 6 relative to those who did not (week 2: 22.3 vs 19.1 μg/mL; week 4: 32.9 vs 26.8 μg/mL; week 6: 36.0 vs 27.2; all *P *\< .001). Similarly, certolizumab pegol concentrations were significantly higher in patients who achieved faecal calprotectin ≤ 250 μg/g at week 6 relative to those who did not (week 2: 22.9 vs 19.8 μg/mL; week 4: 34.9 vs 28.4 μg/mL; week 6: 38.6 vs 30.0 μg/mL; all *P *\< .001). Also, for the composite endpoint of clinical remission (Crohn\'s disease activity index ≤ 150) and faecal calprotectin ≤ 250 μg/g at week 6, higher certolizumab pegol concentrations were observed in those who achieved the outcome vs those who did not at week 2 (22.1 vs 20.6; *P = *.003), week 4 (34.2 vs 30.3; *P *\< .001) and week 6 (38.0 vs 32.0; *P *\< .001) (Table [1](#apt14421-tbl-0001){ref-type="table-wrap"}).

Patients who achieved clinical response, clinical remission, C‐reactive protein ≤ 5 mg/L, or faecal calprotectin ≤ 250 μg/g had significantly higher medians for area under the concentration‐time curve for certolizumab pegol from week 0 to week 6 than those who did not (*P* \< .001 for all; Table [1](#apt14421-tbl-0001){ref-type="table-wrap"}). The differences in exposure were also explored graphically by comparing certolizumab pegol concentration‐time curves (week~0‐6~) for the outcomes C‐reactive protein ≤ 5 mg/L and faecal calprotectin ≤ 250 μg/g at week 6 (Figure [2](#apt14421-fig-0002){ref-type="fig"}).

![Concentration‐time curves (weeks 0‐6) for patients who achieved, or did not achieve (A) C‐reactive protein ≤ 5 mg/L or (B) faecal calprotectin ≤ 250 μg/g at week 6 of treatment with certolizumab pegol. CRP, C‐reactive protein; FC, faecal calprotectin](APT-47-229-g002){#apt14421-fig-0002}

3.4. Logistic regression analysis {#apt14421-sec-0015}
---------------------------------

Multivariable logistic regression was carried out to identify covariates associated with a robust composite outcome of clinical remission (Crohn\'s disease activity index ≤ 150) and faecal calprotectin ≤ 250 μg/g to certolizumab pegol therapy. The composite outcome was achieved by 145/791 patients (18.3%) at week 6 and by 79/425 patients (18.6%) at week 26. Results of univariable associations are shown in Table [S2](#apt14421-sup-0001){ref-type="supplementary-material"}.

The final logistic regression model for induction treatment through week 6 showed that higher certolizumab pegol concentration at week 6 (odds ratio, OR 4.86 \[95% confidence interval, CI 2.20, 10.71\]), no prior anti‐TNF (OR 1.89 \[95% CI 1.14, 3.12\]), higher baseline body weight (OR 1.03 \[95% CI 1.01, 1.04\]), lower baseline C‐reactive protein (OR 0.98 \[95% CI 0.96, 1.00\]), lower baseline Crohn\'s disease activity index (OR 0.99 \[95% CI 0.99, 1.00\]), female gender (OR 1.94 \[95% CI 1.19, 3.16\]) and higher baseline haematocrit (OR 1.13 \[95% CI 1.06, 1.20\]) were independently associated with the composite outcome at week 6 (Table [2](#apt14421-tbl-0002){ref-type="table-wrap"}). The model was able to discriminate responders from non‐responders with a *c*‐statistic of 0.80.

###### 

Multiple logistic regressions for composite endpoint CDAI ≤ 150 and FC ≤ 250 μg/g

                                                                                                                                       Odds ratio (95% CI)   
  ------------------------------------------------------------------------------------------------------------------------------------ --------------------- --------
  Week 6 induction                                                                                                                                           
  CZP concentration at week 6[a](#apt14421-note-0005){ref-type="fn"}                                                                   4.86 (2.20, 10.71)    \<.001
  No prior anti‐TNF                                                                                                                    1.89 (1.14, 3.12)     .013
  Body weight                                                                                                                          1.03 (1.01, 1.04)     \<.001
  CRP                                                                                                                                  0.98 (0.96, 1.00)     .014
  CDAI                                                                                                                                 0.99 (0.99, 1.00)     \<.001
  Gender (female)                                                                                                                      1.94 (1.19, 3.16)     .008
  Haematocrit                                                                                                                          1.13 (1.06, 1.20)     \<.001
  Week 26 maintenance                                                                                                                                        
  CZP concentration at week 6[a](#apt14421-note-0005){ref-type="fn"} ‐ ADAb^‐^ at maintenance[b](#apt14421-note-0006){ref-type="fn"}   15.04 (3.89, 58.19)   \<.001
  CZP concentration at week 6[a](#apt14421-note-0005){ref-type="fn"} ‐ ADAb^+^ at maintenance[b](#apt14421-note-0006){ref-type="fn"}   0.49 (0.07, 3.23)     .456
  CZP concentration at week 12[a](#apt14421-note-0005){ref-type="fn"}                                                                  1.85 (1.28, 2.68)     .001
  Body weight                                                                                                                          1.03 (1.01, 1.05)     \<.001
  CDAI                                                                                                                                 0.99 (0.99, 1.00)     \<.001

ADAb, antidrug antibody; CDAI, Crohn\'s disease activity index; CI, confidence interval; CRP, C‐reactive protein; CZP, certolizumab pegol; FC, faecal calprotectin.

Log‐transformed concentration used in models.

The interaction between the log‐transformed week 6 CZP and maintenance ADAb was statistically significant (*P = *.003).

John Wiley & Sons, Ltd

The final logistic regression model for maintenance treatment through week 26 showed that higher certolizumab pegol concentrations at week 6 in patients who did not develop ADAb to certolizumab pegol (OR 15.04 \[95% CI 3.89, 58.19\]), higher certolizumab pegol concentration at week 12 (OR 1.85 \[95% CI 1.28, 2.68\]), higher baseline body weight (OR 1.03 \[95% CI 1.01, 1.05\]) and lower baseline Crohn\'s disease activity index (OR 0.99 \[95% CI 0.99, 1.00\]), were associated with the composite outcome at week 26 (Table [2](#apt14421-tbl-0002){ref-type="table-wrap"}). The model was able to discriminate responders from non‐responders with a *c*‐statistic of 0.78.

3.5. Threshold analysis {#apt14421-sec-0016}
-----------------------

Although the relationship between certolizumab pegol exposure and response varied among patients, certolizumab pegol concentration thresholds of at least 36.1 μg/mL and 14.8 μg/mL at week 6 and 12 (as defined by the Youden index), respectively, were associated with weeks 6 and 26 efficacy outcomes in receiver operating characteristic analyses (Table [3](#apt14421-tbl-0003){ref-type="table-wrap"} and Figure [S2](#apt14421-sup-0001){ref-type="supplementary-material"}). Thresholds of 44 μg/mL and 48 μg/mL at week 6 were associated with 90% specificity of achieving C‐reactive protein ≤ 5 mg/L or faecal calprotectin ≤ 250 μg/g and with Crohn\'s disease activity index remission or the composite endpoint, respectively, at week 6.

###### 

Receiver operating characteristic analysis of weeks 6 and 12 certolizumab pegol concentrations and weeks 6 and 26 outcomes

  Outcome                                Cut‐point week 6 (μg/mL)   Sensitivity (%)   Specificity (%)   Positive predictive value (%)   Negative predictive value (%)   AUC     Cut‐point week 12 (μg/mL)   Sensitivity (%)   Specificity (%)   Positive predictive value (%)   Negative predictive value (%)   AUC
  -------------------------------------- -------------------------- ----------------- ----------------- ------------------------------- ------------------------------- ------- --------------------------- ----------------- ----------------- ------------------------------- ------------------------------- -------
  Week 6 CDAI response                   31.8\*\*\*                 53.7              57.6              65.8                            45.1                            0.575   ---                         ---               ---               ---                             ---                             ---
  Week 6 CDAI remission                  31.8\*\*\*                 57.5              56.0              44.8                            67.9                            0.578   ---                         ---               ---               ---                             ---                             ---
  Week 6 CRP ≤ 5 mg/L                    31.9\*\*\*                 65.1              68.2              67.7                            64.3                            0.690   ---                         ---               ---               ---                             ---                             ---
  Week 6 FC ≤ 250 μg/g                   32.7\*\*\*                 73.9              60.3              53.2                            79.1                            0.710   ---                         ---               ---               ---                             ---                             ---
  Week 26 FC ≤ 250 μg/g                  ---                        ---               ---               ---                             ---                             ---     13.8\*\*                    68.1              56.0              41.9                            79.0                            0.629
  Week 6 CDAI ≤ 150 and FC ≤ 250 μg/g    34.5\*\*\*                 66.7              59.7              26.8                            89.0                            0.652   ---                         ---               ---               ---                             ---                             ---
  Week 26 CDAI ≤ 150 and FC ≤ 250 μg/g   **36.1\*\*\***             67.1              65.0              22.8                            92.7                            0.668   **14.8\*\*\***              73.2              57.3              28.0                            90.4                            0.669

AUC, area under receiver operator curve; CDAI, Crohn\'s disease activity index; CRP, C‐reactive protein; CZP, certolizumab pegol; FC, faecal calprotectin. \*\*, *P* \< .01; \*\*\*, *P* \< .001.

John Wiley & Sons, Ltd

4. DISCUSSION {#apt14421-sec-0017}
=============

This analysis originated from a large data set that was pooled from nine clinical trials of certolizumab pegol treatment for Crohn\'s disease encompassing 2157 patients with 12 926 analysable records. Our approach of using a population pharmacokinetic model that accounts for the time‐varying nature of covariates allowed for precise simulation of drug concentrations at exact time points. Using simulated data for evaluating the exposure‐response relationship constitutes an improvement over using observed drug concentration data, as this allows data to be pooled from different studies with disparate trial designs and sampling time points, and alleviates common problems such as sampling errors, protocol deviations and missing samples that may confound the results. Our data consistently show that there is a relationship between exposure to certolizumab pegol and clinically important outcomes at the end of induction (week 6) and maintenance therapy (week 26) with certolizumab pegol. Taken together, the exposure‐response data could provide an opportunity to enhance clinical outcomes for patients with Crohn\'s disease that are treated with certolizumab pegol.

Median certolizumab pegol concentrations were higher in patients who achieved clinical response and/or remission, as well as biologic remission defined by objective markers of inflammation like C‐reactive protein and faecal calprotectin. These findings are consistent with findings of other TNF antagonists, as previously an inverse relationship was shown between serum concentrations of infliximab and levels of C‐reactive protein.[16](#apt14421-bib-0016){ref-type="ref"} Furthermore, median concentrations of infliximab have also been associated with mucosal healing,[17](#apt14421-bib-0017){ref-type="ref"} and higher trough concentrations of adalimumab were associated with clinical response to dose escalation.[18](#apt14421-bib-0018){ref-type="ref"} In patients with ulcerative colitis, an exposure‐response relationship was shown for infliximab and golimumab.[19](#apt14421-bib-0019){ref-type="ref"}, [20](#apt14421-bib-0020){ref-type="ref"}

Quartile analyses based on certolizumab pegol concentration showed consistently that higher certolizumab pegol concentrations are associated with clinical response, clinical remission, C‐reactive protein ≤ 5 mg/L, faecal calprotectin ≤ 250 μg/g, and a composite outcome of clinical remission and faecal calprotectin ≤ 250 μg/g. A stronger relationship (\~45% increase in the proportion of patients achieving the outcome from first to fourth quartile) was observed for objective markers of inflammation such as C‐reactive protein and faecal calprotectin. These data support previous analyses showing that higher concentrations of certolizumab pegol are positively associated with endoscopic remission.[1](#apt14421-bib-0001){ref-type="ref"}

Previous analyses examining associations between certolizumab pegol concentrations and Crohn\'s disease activity index had mixed results.[1](#apt14421-bib-0001){ref-type="ref"}, [7](#apt14421-bib-0007){ref-type="ref"}, [14](#apt14421-bib-0014){ref-type="ref"}, [16](#apt14421-bib-0016){ref-type="ref"}, [21](#apt14421-bib-0021){ref-type="ref"} Objective markers of inflammation and severity of Crohn\'s disease include C‐reactive protein and faecal calprotectin, which have been associated with disease activity and endoscopic healing.[22](#apt14421-bib-0022){ref-type="ref"}, [23](#apt14421-bib-0023){ref-type="ref"}, [24](#apt14421-bib-0024){ref-type="ref"} Specifically, faecal calprotectin values of ≤ 250 μg/g are indicative of endoscopic remission.[23](#apt14421-bib-0023){ref-type="ref"} In the present analyses, C‐reactive protein and faecal calprotectin were included as efficacy outcomes and these biomarkers were significantly associated with certolizumab pegol concentrations. Interestingly, sensitivity analyses showed that varying the faecal calprotectin threshold (50 μg/g vs 175 μg/g vs 250 μg/g) did not significantly change the discriminatory power of certolizumab pegol concentrations (data not shown). The robust composite outcome of Crohn\'s disease activity index ≤ 150 with faecal calprotectin ≤ 250 μg/g encompassed both clinical and endoscopic remission indicators, and was significantly associated with higher certolizumab pegol concentrations at both weeks 6 and 12. We recognise that a limitation of our study is that historic trials in Crohn\'s disease did not routinely assess endoscopic outcomes and thus these data were not available for analysis. However, a range of clinically important outcomes were evaluated, some of which are routinely used in clinical practice, and may improve the application of our results in real life.

The multivariable analysis showed that when patients were negative for ADAb to certolizumab pegol, drug concentrations at week 6 were significantly associated with the composite outcome at week 26. Previously, the presence of ADAb has been associated with increased clearance of TNF antagonists,[10](#apt14421-bib-0010){ref-type="ref"} increased incidence of adverse events[25](#apt14421-bib-0025){ref-type="ref"} and with loss of response to treatment.[26](#apt14421-bib-0026){ref-type="ref"} However, until now, it has been difficult to directly associate the presence or absence of ADAb with efficacy endpoints.

The receiver operating characteristic analyses showed moderate sensitivity and specificity for various certolizumab pegol concentration thresholds for the outcomes described here. Although the relationship between certolizumab pegol exposure and response varied among patients, approximate concentrations of at least 36 μg/mL and 15 μg/mL certolizumab pegol at weeks 6 and 12 were associated with weeks 6 and 26 outcomes. Previously, receiver operating characteristic analyses of adalimumab exposure and response relationships revealed that higher concentrations of adalimumab were predictive of improvements in C‐reactive protein and clinical remission, however, these relationships were not observed if the presence of ADAb was assessed.[27](#apt14421-bib-0027){ref-type="ref"}

Measurements of ADAbs may vary from one testing method to another, presenting a challenge for interpreting the data. Ligand‐binding assays are the most common method of ADAb measurement. One such assay, ELISA, is used in these studies but it is susceptible to non‐specific binding and false‐positive findings. Several commercial assays for various anti‐TNF antibodies are available. A new assay for measuring certolizumab pegol and certolizumab pegol‐ADAb has recently been introduced, which may address some of these concerns (Miraca Life Sciences, Inc., Irving, TX, USA).[28](#apt14421-bib-0028){ref-type="ref"}, [29](#apt14421-bib-0029){ref-type="ref"} One limitation of our study was the assay used to measure ADAb, which was drug sensitive and not able to detect ADAb in samples with detectable certolizumab pegol.

It has been proposed that therapeutic drug monitoring of TNF antagonists has the potential to be useful for predicting or preventing treatment failure in patients with Crohn\'s disease, and it may be helpful for deciding therapeutic interventions after primary loss of efficacy,[8](#apt14421-bib-0008){ref-type="ref"} and to make treatment more cost‐effective.[30](#apt14421-bib-0030){ref-type="ref"} Knowledge of specific drug concentration thresholds that correspond with efficacy outcomes, as identified in this analysis, may inform therapeutic drug monitoring and guide decisions in clinical practice.

Overall, these results suggest that achieving higher concentrations of certolizumab pegol during induction and maintenance therapy may improve biological and clinical response. The large size of this data set and the multiple analytical approaches constitute an important improvement over previous exposure‐response analyses.[14](#apt14421-bib-0014){ref-type="ref"}, [16](#apt14421-bib-0016){ref-type="ref"}, [31](#apt14421-bib-0031){ref-type="ref"} These results now need to be corroborated in a prospective, interventional study including endoscopic outcomes that will test the approach of dosing based on drug exposure, by using the described population pharmacokinetic model to calculate, in individual patients, the exact dose needed to achieve the proposed certolizumab pegol concentration thresholds.
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